文献速递浆细胞疾病

单克隆浆细胞疾病中的RAS/RAF突变图谱

RAS/RAF landscape in monoclonal plasma cell conditions.
PubMed 文献 · Blood · 2024-01-01

该研究利用常规二代测序 panel 分析了超过 10000 例不同浆细胞疾病患者,描述 RAS/RAF 突变图谱;约 61% 患者在诊断或复发时携带 RAS/RAF 突变,症状前病例频率更低,突变谱与实体瘤不同(Q61 突变比例更高),29 例双突变患者单细胞测序显示突变多位于不同亚克隆。

要点

  • 约 61% 的浆细胞疾病患者在诊断或复发时携带 RAS/RAF 突变,症状前病例频率更低。
  • 浆细胞疾病中 RAS/RAF 突变谱与实体瘤不同,Q61 突变比例更高。
  • 29 例双突变患者单细胞测序显示突变多位于不同亚克隆,提示持续突变过程。

核心结论

  • RAS/RAF 通路在治疗和残留病评估方面均不是有吸引力的靶点。

研究设计与样本

  • 利用常规二代测序 panel 分析超过 10000 例不同浆细胞疾病患者,描述 RAS/RAF 突变图谱。

主要发现

  • 在该大型队列中,几乎 61% 的患者在诊断或复发时存在 RAS/RAF 突变,而症状前病例中频率低得多。
  • 突变谱与实体瘤中观察到的不同,Q61 突变比例更高。
  • 29 例携带两种不同突变的患者行单细胞测序,多数病例中突变位于不同亚克隆,提示正在进行的突变过程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma is characterized by a huge heterogeneity at the molecular level. The RAS/RAF pathway is the most frequently mutated, in ∼50% of the patients. However, these mutations are frequently subclonal, suggesting a secondary event. Because these genes are part of our routine next-generation sequencing panel, we analyzed >10 000 patients with different plasma cell disorders to describe the RAS/RAF landscape. In this large cohort of patients, almost 61% of the patients presented a RAS/RAF mutation at diagnosis or relapse, but much lower frequencies occurred in presymptomatic cases. Of note, the mutations were different from that observed in solid tumors (higher proportions of Q61 mutations). In 29 patients with 2 different mutations, we were able to perform single-cell sequencing, showing that in most cases, mutations occurred in different subclones, suggesting an ongoing mutational process. These findings suggest that the RAS/RAF pathway is not an attractive target, both on therapeutic and residual disease assessment points of view.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schavgoulidze A, Corre J, Samur MK, et al. RAS/RAF landscape in monoclonal plasma cell conditions. Blood. 2024. PMID: 38643494. doi:10.1182/blood.2023022295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。